BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 30401645)

  • 21. [OMICS and biomarkers of glial tumors].
    Idbaih A
    Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
    Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
    Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
    Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.
    Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO
    Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
    Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
    J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptome analyses reveal molecular mechanisms underlying phenotypic differences among transcriptional subtypes of glioblastoma.
    Pan YB; Wang S; Yang B; Jiang Z; Lenahan C; Wang J; Zhang J; Shao A
    J Cell Mol Med; 2020 Apr; 24(7):3901-3916. PubMed ID: 32091665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
    Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses.
    Yuan F; Yi L; Hai L; Wang Y; Yang Y; Li T; Tong L; Ma H; Liu P; Ming H; Ren B; Yu S; Lin Y; Yang X
    Dis Markers; 2019; 2019():7049294. PubMed ID: 31772693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue Proteome Analysis of Different Grades of Human Gliomas Provides Major Cues for Glioma Pathogenesis.
    Gollapalli K; Ghantasala S; Atak A; Rapole S; Moiyadi A; Epari S; Srivastava S
    OMICS; 2017 May; 21(5):275-284. PubMed ID: 28481733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glioblastoma: pathology, molecular mechanisms and markers.
    Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A
    Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
    Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
    Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioinformatic analyses reveal the key pathways and genes in the CXCR4 mediated mesenchymal subtype of glioblastoma.
    Yi L; Tong L; Li T; Hai L; Abeysekera IR; Tao Z; Ma H; Liu P; Xie Y; Li J; Yuan F; Yu S; Yang X
    Mol Med Rep; 2018 Jul; 18(1):741-748. PubMed ID: 29767255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses.
    Conroy S; Wagemakers M; Walenkamp AM; Kruyt FA; den Dunnen WF
    J Neurooncol; 2017 Jan; 131(1):11-20. PubMed ID: 27633774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
    Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W
    Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
    Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
    Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
    Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
    J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptome analysis reveals distinct gene expression profiles in astrocytoma grades II-IV.
    Narsia N; Ramagiri P; Ehrmann J; Kolar Z
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):261-271. PubMed ID: 28452381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells.
    Safaee M; Fakurnejad S; Bloch O; Clark AJ; Ivan ME; Sun MZ; Oh T; Phillips JJ; Parsa AT
    PLoS One; 2015; 10(2):e0111532. PubMed ID: 25714433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
    Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
    Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.